13 results
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
or distribution;
we may be required to conduct additional clinical trials or post-approval studies;
we may be required to recall a product or change the way … ; or
seize or detain products, or require a product recall.
Any government investigation of alleged violations of law could require us to expend
10-K
2021 FY
CGTX
Cognition Therapeutics Inc
30 Mar 22
Annual report
7:40am
ability to recall fear-inducing triggers and its performance in a maze. The mice exhibiting symptoms of AD, depicted by the red bars in the image below … manufacture or distribution;
we may be required to conduct additional clinical trials or post-approval studies;
we may be required to recall a product
10-Q
2021 Q3
CGTX
Cognition Therapeutics Inc
17 Nov 21
Quarterly report
5:15pm
manufacture or distribution;
we may be required to conduct additional clinical trials or post-approval studies;
we may be required to recall a product … operations, including closing our contract manufacturers’ facilities; or
seize or detain products, or require a product recall.
Any government
DRS
24uyyt362wpfhq
20 Oct 22
Draft registration statement
12:00am
424B4
225y147g1m238ot3j
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
bopikc6 g7jj0494jy
19 Jul 21
IPO registration
7:02am
DRS
cric bwlyjyixjp9s
7 May 21
Draft registration statement
12:00am
DRS/A
4qfsf94 qisuu
23 Jun 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next